Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease.
The study, which was an early-phase 46-patient trial intended to provide preliminary results regarding safety and efficacy, tested a strategy involving injections of paclitaxel into the abdomen and injections of gemcitabine and nab-paclitaxel (a combination of paclitaxel and a protein called albumin) into the blood.
The treatment had acceptable toxicities, and patients had a median survival time of 14.5 months, with a 1-year survival rate of 60.9%.
“Now, a phase 3 study to compare survival outcomes between this therapy and standard chemotherapy has been launched,” said senior author Sohei Satoi, MD, of Kansai Medical University, in Japan.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1002/bjs.11792
About Journal
BJS (British Journal of Surgery incorporating the European Journal of Surgery) is the premier peer-reviewed surgical journal in Europe. BJS has a tradition of publishing high-quality papers in breast, upper GI, lower GI, vascular, HPB, and endocrine surgery, and surgical sciences. Content includes Leading Articles, Reviews, Original Research Articles, Systematic Reviews, Meta-analyses and Randomized Clinical Trials.
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.